Navigation Links
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Date:8/19/2007

hich should not be given to healthy volunteers, this evaluation is being done in previously untreated elderly patients with de novo poor-risk AML who receive Cloretazine(R) (VNP40101M) therapy.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. A Phase II trial of Cloretazine(R) (VNP40101M) in small cell lung cancer is also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. In preclinical studies, Vion is also evaluating VNP40541, a hypoxia-selective compound, and hydrazone compounds. The Company also is seeking development partners for TAPET(R), its modified Salmonella vector used to deliver anticancer agents directly to tumors. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations, the inability to access capital and f
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... N.C. , Nov. 25, 2014  At the ... Antonio this October, KaVo Kerr Group was ... Technology Expo, offering attendees the opportunity to see and ... well-respected key opinion leaders deliver lectures on the latest ... Group products include the new DEXIS CariVu Caries Detection ...
(Date:11/26/2014)... Nov. 25, 2014  Medtronic,s roughly $43 ... been widely discussed in the media for its ... a stronger leading player in one of the ... The healthcare market research firm said  the two ... a diverse set of solutions spanning inpatient to ...
(Date:11/26/2014)...  Unilife Corporation (NASDAQ: UNIS, ASX: UNS), a designer, ... announced that its Chairman and CEO, Alan Shortall ... 26th Annual Healthcare Conference at the New York Palace ... 2014. The conference presentation will be ... Webcast. To listen, please go to: http://ir.unilife.com/events.cfm . ...
Breaking Medicine Technology:KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 3Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 2Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 3Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2
(Date:11/27/2014)... According to a recent report by iData ... into the surgical robotics market may find ... MIS field dominated by Intuitive. These companies are expected ... market by 2020. , “The MIS robotic device ... and President of iData. “System sales for the da ...
(Date:11/27/2014)... 2014 Blood-borne pathogens raise the risk ... and procedures in place to counter this. However, it ... things tainted with menstrual blood are taken as seriously. ... more sanitary way to handle tampons and menstrual pads ... Sonora, Calif. , He then created a prototype of ...
(Date:11/27/2014)... Randy Dotinga HealthDay Reporter ... brains seem pre-wired to acquire a second language, new research ... tongue will likely gain a brain boost, the small study ... after learning," said study co-author Ping Li, co-director of the ... But it,s even more interesting, Li said, that "the brain ...
(Date:11/27/2014)... 2014 In order to enable people to ... designed an easy way to avoid touching a toilet seat ... created a prototype of the patent-pending Toilet Tamer, a device ... seat and/or lid in a more sanitary manner. It avoids ... germs. Overall, it promotes good hygiene and peace of mind. ...
(Date:11/27/2014)... New York (PRWEB) November 27, 2014 ... individuals who were allegedly injured by the medication are ... a federal litigation is looking ahead to a status ... According to a Scheduling Order issued earlier this year, ... on December 16th at 10:00 a.m. Items likely to ...
Breaking Medicine News(10 mins):Health News:U.S. Robotic Surgery Market Set to Diversify and Grow: Intuitive Surgical’s ‘da Vinci’ Robot Revenues to Increasingly Rely On Procedures and Services 2Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 3
... , THURSDAY, Jan. 27 (HealthDay News) -- Work-related hearing loss ... Israeli researchers gave hearing tests to 298 male employees ... and found that 99 of the workers had a hearing ... tended to be older and to have been exposed to ...
... A new University of Illinois study provides convincing evidence ... matters, and also suggests that teaming broccoli with broccoli ... as powerful. "Broccoli, prepared correctly, is an extremely ... enough to have an effect. To get broccoli,s benefits, ...
... terrorist events causes deterioration of psychological resources, such as commitment ... in turn can also lead to loss of resources and ... study at the University of Haifa. "Mass media plays a ... present study shows that watching this type of coverage on ...
... are pregnant? Is it just certain groups? What kind of ... Norwegian Institute of Public Health provides some answers. The study ... Cohort Study. "We know little about the consumption ... study was to find out what is consumed and the ...
... Day 2011, on 4 February, the Africa Oxford Cancer ... (ESMO) are working together to raise international awareness of ... and ESMO are launching the ,Cancer in Africa: the ... to stop the train and prevent as many cancer ...
... be treated by electric stimulation, also known as shockable ... settings than in the home, according to a National ... issue of the New England Journal of Medicine ... arrests under various scenarios. For example, the study considered ...
Cached Medicine News:Health News:Sprouts? Supplements? Team them up to boost broccoli's cancer-fighting power 2Health News:Watching TV coverage of terror makes viewers feel threatened 2Health News:Organic food in pregnancy -- new study 2Health News:International community called upon to stop the runaway train of cancer in Africa 2Health News:Shockable cardiac arrests are more common in public than home 2Health News:Shockable cardiac arrests are more common in public than home 3
The inner wall of the tube is coated with spray-dried lithium, ammonium or sodium heparin. These additives are anti-coagulants, which activate anti-thrombins, thus blocking the coagulation cascade of...
BD Vacutainer® Heparin Tubes are spray-coated with either lithium heparin or sodium heparin and are used for plasma determinations in chemistry....
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Medicine Products: